JP2008534627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534627A5 JP2008534627A5 JP2008504532A JP2008504532A JP2008534627A5 JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5 JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5
- Authority
- JP
- Japan
- Prior art keywords
- amylin
- seq
- disorder
- disease
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (24)
- 気分障害、不安障害または精神分裂病である精神の疾患または障害を治療するための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。 - 該疾患または障害が不安障害である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 該不安障害が強迫障害である、請求項２記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 疾患または障害が鬱病である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 疾患または障害が精神分裂病である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 該化合物が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項１〜５のいずれか１記載のアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 請求項１〜５のいずれかのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体を含む医薬上許容される組成物。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項６記載の医薬上許容される組成物。
- 気分障害、不安障害または精神分裂病である精神の疾患または障害を治療するための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体を含む医薬組成物であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該医薬組成物。 - 該疾患または障害が不安障害である請求項９記載の医薬組成物。
- 該不安障害が強迫障害である請求項１０記載の医薬組成物。
- 疾患または障害が鬱病である請求項９記載の医薬組成物。
- 疾患または障害が精神分裂病である請求項９記載の医薬組成物。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項９記載の医薬組成物。
- 気分障害、不安障害または精神分裂病である精神の疾患または障害の治療用医薬の製造のための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体の使用であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではないことを特徴とする該使用。 - 疾患または障害が不安障害であることを特徴とする請求項１５記載の使用。
- 不安障害が強迫障害であることを特徴とする請求項１６記載の使用。
- 疾患または障害が鬱病であることを特徴とする請求項１５記載の使用。
- 疾患または障害が精神分裂病であることを特徴とする請求項１５記載の使用。
- 少なくとも１つの他の精神医薬が対象に投与されることを特徴とする請求項１５記載の使用。
- 精神障害を治療用医薬の製造のための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体の使用であって、
医薬が該障害を治療するために有効な量で投与され、物質関連障害が、物質依存、物質嗜癖、物質誘導不安障害および物質誘導気分障害よりなる群から選択される該使用。 - 物質関連障害が、物質嗜癖、物質誘導不安障害または物質誘導気分障害であることを特徴とする請求項２１記載の使用。
- 少なくとも１つの他の精神医薬が対象に投与されることを特徴とする請求項２２記載の使用。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択されることを特徴とする請求項１５〜２３のいずれか１記載の使用。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66668105P | 2005-03-31 | 2005-03-31 | |
| US66733505P | 2005-03-31 | 2005-03-31 | |
| US60/666,681 | 2005-03-31 | ||
| US60/667,335 | 2005-03-31 | ||
| US67544105P | 2005-04-28 | 2005-04-28 | |
| US60/675,441 | 2005-04-28 | ||
| US76058306P | 2006-01-20 | 2006-01-20 | |
| US60/760,583 | 2006-01-20 | ||
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534627A JP2008534627A (ja) | 2008-08-28 |
| JP2008534627A5 true JP2008534627A5 (ja) | 2009-05-21 |
| JP5114381B2 JP5114381B2 (ja) | 2013-01-09 |
Family
ID=37054153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504532A Expired - Fee Related JP5114381B2 (ja) | 2005-03-31 | 2006-03-31 | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
| JP2008504396A Expired - Fee Related JP5415067B2 (ja) | 2005-03-31 | 2006-03-31 | 肥満および摂食障害の制御、防止および治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504396A Expired - Fee Related JP5415067B2 (ja) | 2005-03-31 | 2006-03-31 | 肥満および摂食障害の制御、防止および治療のための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7879794B2 (ja) |
| EP (5) | EP2135617A3 (ja) |
| JP (2) | JP5114381B2 (ja) |
| KR (3) | KR20130122983A (ja) |
| CN (3) | CN101189021B (ja) |
| AT (2) | ATE480255T1 (ja) |
| AU (2) | AU2006230420B2 (ja) |
| BR (2) | BRPI0609595A8 (ja) |
| CA (2) | CA2602261A1 (ja) |
| DE (2) | DE602006016760D1 (ja) |
| DK (1) | DK1888094T3 (ja) |
| EA (1) | EA013121B1 (ja) |
| ES (1) | ES2330671T3 (ja) |
| IL (1) | IL186200A (ja) |
| MX (2) | MX2007012237A (ja) |
| NZ (3) | NZ561936A (ja) |
| WO (2) | WO2006105527A2 (ja) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| CA2556226A1 (en) * | 2004-02-11 | 2006-08-10 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| MX2007012237A (es) | 2005-03-31 | 2007-12-07 | Amylin Pharmaceuticals Inc | Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos. |
| WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| WO2007104789A2 (en) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| KR20080106950A (ko) * | 2006-03-31 | 2008-12-09 | 아밀린 파마슈티칼스, 인크. | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 |
| DK2020990T3 (da) | 2006-05-30 | 2010-12-13 | Intarcia Therapeutics Inc | Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem |
| KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
| ES2389747T3 (es) | 2007-02-05 | 2012-10-31 | Amylin Pharmaceuticals, Inc. | Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad |
| ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
| DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
| US20110152183A1 (en) * | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| JP5703226B2 (ja) * | 2008-10-21 | 2015-04-15 | ノヴォ ノルディスク アー／エス | アミリン誘導体 |
| DK2373681T3 (en) | 2008-12-10 | 2017-04-24 | Glaxosmithkline Llc | PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID |
| WO2010085700A2 (en) * | 2009-01-22 | 2010-07-29 | Unigene Laboratories Inc. | Treatment for obesity |
| EP2416797A4 (en) * | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| WO2010123930A2 (en) | 2009-04-20 | 2010-10-28 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| RU2753280C2 (ru) | 2009-09-28 | 2021-08-12 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| US20110317346A1 (en) | 2010-06-28 | 2011-12-29 | Zte Corporation | Totally-enclosed integrative access system and power consumption reduction method thereof |
| CA2815024A1 (en) | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| CA2823397C (en) | 2011-01-07 | 2020-03-10 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| CA3080189C (en) * | 2011-06-17 | 2023-01-17 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| KR20230095124A (ko) | 2012-01-06 | 2023-06-28 | 앤지 파마 유에스 엘엘씨 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| AU2013211929B2 (en) * | 2012-01-26 | 2016-05-26 | Christopher J. Soares | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| EP3027644B1 (en) * | 2013-07-30 | 2019-08-21 | Christopher J. Soares | Cgrp agonist peptides |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| KR102650751B1 (ko) | 2015-06-03 | 2024-03-22 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
| TWI814219B (zh) | 2016-05-16 | 2023-09-01 | 美商因塔希亞治療公司 | 升糖素受體選擇性多肽和彼之使用方法 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| IL265099B2 (en) | 2016-09-02 | 2024-09-01 | Christopher J Soares | Pharmaceutical compositions comprising an effective amount of calcitonin gene-related peptide (cgrp) receptor antagonist or pharmaceutically acceptable salt thereof, for treating glaucoma |
| US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| EP3628233B1 (en) * | 2018-09-28 | 2021-06-02 | Siemens Healthcare GmbH | Method and system for providing a dose reference value for a patient |
| US11443843B2 (en) | 2019-01-04 | 2022-09-13 | International Business Machines Corporation | Personal customized guidance for treating patients |
| CN111700904A (zh) * | 2020-07-31 | 2020-09-25 | 江南大学 | 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法 |
| WO2025120001A1 (en) * | 2023-12-04 | 2025-06-12 | Zealand Pharma A/S | Amylin analogues for reducing consumption of high-fat food |
| WO2025120002A1 (en) * | 2023-12-04 | 2025-06-12 | Zealand Pharma A/S | Petrelintide for reducing weight whilst preserving lean mass |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0024807B1 (en) | 1979-07-28 | 1983-11-02 | Beecham Group Plc | Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US4401593A (en) | 1982-02-12 | 1983-08-30 | Armour Pharmaceutical Company | Glycine - 8 calcitonin |
| US4397780A (en) | 1982-02-12 | 1983-08-09 | Armour Pharmaceutical Company | Leucine22 -calcitonin |
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4497731A (en) | 1983-04-04 | 1985-02-05 | Armour Pharmaceutical Company | Glycine 8-des-tyrosine 22 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4597900A (en) | 1983-08-22 | 1986-07-01 | Armour Pharmaceutical Co. | Des2 -glycine8 -des22 -calcitonin |
| US4537716A (en) | 1983-12-05 | 1985-08-27 | Armour Pharmaceutical Co. | Des-serine2 or des-glycine2 -leucine22 calcitonin |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4604238A (en) | 1984-12-10 | 1986-08-05 | Armour Pharmaceutical Company | Analogs of calcitonin |
| US4606856A (en) | 1985-03-18 | 1986-08-19 | Seyler Jay K | [Des-1-amino, 8-glycine]calcitonin |
| US4652627A (en) | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
| US4687839A (en) | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
| US4697002A (en) | 1985-12-23 | 1987-09-29 | Kempe Tomas G | Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36 |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5405831A (en) * | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| ATE205854T1 (de) * | 1991-11-19 | 2001-10-15 | Amylin Pharmaceuticals Inc | Peptide als amylin-agonisten und ihre verwendung |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
| KR100429966B1 (ko) | 1993-09-07 | 2004-05-04 | 아밀린 파마슈티칼스, 인크. | 위장 운동성 조절을 위한 제약 조성물 |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| US5677279A (en) * | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US6307018B1 (en) | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
| DE69831673C5 (de) | 1997-01-07 | 2015-01-22 | Amylin Pharmaceuticals, Llc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) * | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| ATE354584T1 (de) | 1997-06-13 | 2007-03-15 | Gryphon Therapeutics Inc | Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen |
| DE69942453D1 (de) | 1998-05-29 | 2010-07-15 | Jgc Catalysts & Chemicals Ltd | Verfahren zur herstellung photoelektrischer zellen |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| EP1107979B1 (en) | 1998-08-31 | 2006-07-05 | Gryphon Therapeutics, Inc. | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| AU2001273385B2 (en) | 2000-09-08 | 2005-04-07 | Gryphon Therapeutics, Inc. | Polymer-modified synthetic proteins |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
| US7884182B2 (en) | 2001-11-14 | 2011-02-08 | Amylin Pharmaceuticals, Inc. | Chemical peptide ligation with three or more components |
| NZ534557A (en) * | 2002-01-08 | 2007-10-26 | Amylin Pharmaceuticals Inc | Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels |
| AR040126A1 (es) * | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| EP1511760B1 (en) | 2002-06-10 | 2006-01-18 | Geneprot, Inc. | Carboxy protection strategies for acidic c-terminal amino acids in chemical ligation of oligopeptides |
| AU2003298739A1 (en) | 2002-11-26 | 2004-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| US20060275768A1 (en) | 2002-12-30 | 2006-12-07 | Kochendoerfer Gerd G | Multiplex polymer ligation |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| WO2004105685A2 (en) | 2003-05-22 | 2004-12-09 | Gryphon Therapeutics, Inc. | Displaceable linker solid phase chemical ligation |
| CA2556226A1 (en) | 2004-02-11 | 2006-08-10 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| CN101035806A (zh) | 2004-10-08 | 2007-09-12 | 安米林药品公司 | 新的糊精家族多肽－6（afp－6）类似物和制备和使用它们的方法 |
| MX2007012237A (es) | 2005-03-31 | 2007-12-07 | Amylin Pharmaceuticals Inc | Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos. |
-
2006
- 2006-03-31 MX MX2007012237A patent/MX2007012237A/es active IP Right Grant
- 2006-03-31 BR BRPI0609595A patent/BRPI0609595A8/pt not_active IP Right Cessation
- 2006-03-31 US US11/910,214 patent/US7879794B2/en not_active Expired - Fee Related
- 2006-03-31 BR BRPI0606466-3A patent/BRPI0606466A2/pt not_active IP Right Cessation
- 2006-03-31 DK DK06749305T patent/DK1888094T3/da active
- 2006-03-31 ES ES06749305T patent/ES2330671T3/es active Active
- 2006-03-31 EP EP09009392.3A patent/EP2135617A3/en not_active Withdrawn
- 2006-03-31 AU AU2006230420A patent/AU2006230420B2/en not_active Ceased
- 2006-03-31 WO PCT/US2006/012601 patent/WO2006105527A2/en active Application Filing
- 2006-03-31 EP EP06749305A patent/EP1888094B1/en active Active
- 2006-03-31 AT AT06740117T patent/ATE480255T1/de not_active IP Right Cessation
- 2006-03-31 DE DE602006016760T patent/DE602006016760D1/de active Active
- 2006-03-31 NZ NZ561936A patent/NZ561936A/en not_active IP Right Cessation
- 2006-03-31 DE DE602006008456T patent/DE602006008456D1/de active Active
- 2006-03-31 CA CA002602261A patent/CA2602261A1/en not_active Abandoned
- 2006-03-31 EP EP10008733A patent/EP2248527A3/en not_active Withdrawn
- 2006-03-31 EA EA200702126A patent/EA013121B1/ru not_active IP Right Cessation
- 2006-03-31 CA CA002602584A patent/CA2602584A1/en not_active Abandoned
- 2006-03-31 US US11/910,206 patent/US7671023B2/en not_active Expired - Fee Related
- 2006-03-31 MX MX2007012236A patent/MX2007012236A/es active IP Right Grant
- 2006-03-31 EP EP06740117A patent/EP1871403B1/en active Active
- 2006-03-31 CN CN2006800192236A patent/CN101189021B/zh not_active Expired - Fee Related
- 2006-03-31 NZ NZ578299A patent/NZ578299A/en not_active IP Right Cessation
- 2006-03-31 EP EP10008998.6A patent/EP2258382A3/en not_active Withdrawn
- 2006-03-31 NZ NZ578298A patent/NZ578298A/en not_active IP Right Cessation
- 2006-03-31 JP JP2008504532A patent/JP5114381B2/ja not_active Expired - Fee Related
- 2006-03-31 AU AU2006230602A patent/AU2006230602B2/en not_active Ceased
- 2006-03-31 KR KR1020137025456A patent/KR20130122983A/ko not_active Ceased
- 2006-03-31 AT AT06749305T patent/ATE439140T1/de active
- 2006-03-31 KR KR1020077025152A patent/KR101383493B1/ko not_active Expired - Fee Related
- 2006-03-31 KR KR1020077025124A patent/KR20080003849A/ko not_active Abandoned
- 2006-03-31 CN CN2011102204917A patent/CN102343084A/zh active Pending
- 2006-03-31 JP JP2008504396A patent/JP5415067B2/ja not_active Expired - Fee Related
- 2006-03-31 WO PCT/US2006/011768 patent/WO2006105345A2/en active Application Filing
- 2006-10-04 CN CNA2006800541222A patent/CN101415435A/zh active Pending
-
2007
- 2007-09-24 IL IL186200A patent/IL186200A/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,733 patent/US20100125054A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,516 patent/US8278267B2/en not_active Expired - Fee Related
-
2011
- 2011-05-20 US US13/112,290 patent/US8389477B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 US US13/631,577 patent/US20130225485A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,149 patent/US20130184213A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534627A5 (ja) | ||
| JP2019031502A5 (ja) | ||
| Bourne et al. | Sleep disruption in critically ill patients–pharmacological considerations | |
| Kruk-Slomka et al. | Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system | |
| JP2010535252A5 (ja) | ||
| JP2014517050A5 (ja) | ||
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| JP2010529118A5 (ja) | ||
| JP2007523168A5 (ja) | ||
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| JP2005506370A5 (ja) | ||
| JP2008540356A (ja) | 薬物乱用の治療方法 | |
| EP2283843A3 (en) | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) | |
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
| JP2007516193A5 (ja) | ||
| JP2011507861A5 (ja) | ||
| JP2014506933A5 (ja) | ||
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| JP2022180531A5 (ja) | ||
| JP2007509960A5 (ja) | ||
| JP2008533079A5 (ja) | ||
| JP2011524898A5 (ja) | ||
| JP2011500589A5 (ja) | ||
| JP2011500819A5 (ja) |